J
Jie Liu
Researcher at Stanford University
Publications - 34
Citations - 2295
Jie Liu is an academic researcher from Stanford University. The author has contributed to research in topics: Antibody & Monoclonal antibody. The author has an hindex of 13, co-authored 34 publications receiving 1498 citations.
Papers
More filters
Journal ArticleDOI
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Jie Liu,Lijuan Wang,Feifei Zhao,Serena Tseng,Cyndhavi Narayanan,Lei Shura,Stephen B. Willingham,Maureen Howard,Susan S. Prohaska,Jens Peter Volkmer,Mark P. Chao,Irving L. Weissman,Ravindra Majeti +12 more
TL;DR: Hu5F9-G4 induced potent macrophage-mediated phagocytosis of primaryhuman AML cells in vitro and completely eradicated human AML in vivo, leading to long-term disease-free survival of patient-derived xenografts.
Journal ArticleDOI
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Branimir I. Sikic,Nehal Lakhani,Amita Patnaik,Sumit A. Shah,Sreenivasa R Chandana,Drew W. Rasco,A. Dimitrios Colevas,Timothy J. O'Rourke,Sujata Narayanan,Kyriakos P. Papadopoulos,George A. Fisher,Victor M. Villalobos,Susan S. Prohaska,Maureen Howard,Muralidhar Beeram,Mark P. Chao,Balaji Agoram,James Y. Chen,Jie Huang,Matthew Axt,Jie Liu,Jens-Peter Volkmer,Ravindra Majeti,Irving L. Weissman,Chris H. Takimoto,Dana Supan,Heather A. Wakelee,Rhonda Aoki,Mark D. Pegram,Sukhmani K. Padda +29 more
TL;DR: 5F9 is well tolerated using a priming dose at 1mg/kg on day 1 followed by maintenance doses of up to 45 mg/kg weekly, and the half-life of approximately 13 days was observed.
Journal ArticleDOI
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Kipp Weiskopf,Nadine Jahchan,Peter J. Schnorr,Sandra Cristea,Aaron M. Ring,Roy Louis Maute,Anne Kathrin Volkmer,Jens Peter Volkmer,Jie Liu,Jing Shan Lim,Dian Yang,Garrett Seitz,Thuyen Nguyen,Di Wu,Kevin Jude,Heather Guerston,Amira A. Barkal,Francesca Trapani,Julie George,John T. Poirier,Eric E. Gardner,Linde A. Miles,Elisa de Stanchina,Shane Lofgren,Hannes Vogel,Monte M. Winslow,Caroline Dive,Roman K. Thomas,Charles M. Rudin,Matt van de Rijn,Ravindra Majeti,K. Christopher Garcia,Irving L. Weissman,Julien Sage +33 more
TL;DR: Disruption of the interaction of CD47 with SIRPα using anti-CD47 antibodies induced macrophage-mediated phagocytosis of human SCLC patient cells in culture, and this approach could enable personalized immunotherapeutic regimens in patients with S CLC and other cancers.
Journal ArticleDOI
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
Sharareh Gholamin,Sharareh Gholamin,Siddhartha Mitra,Abdullah H. Feroze,Jie Liu,Suzana Assad Kahn,Michael Zhang,Rogelio Esparza,Chase Richard,Vijay Ramaswamy,Marc Remke,Marc Remke,Anne Kathrin Volkmer,Anne Kathrin Volkmer,Stephen B. Willingham,Anitha Ponnuswami,Aaron McCarty,Patricia Lovelace,Theresa A. Storm,Simone Schubert,Gregor Hutter,Cyndhavi Narayanan,Pauline Chu,Eric H. Raabe,Griffith R. Harsh,Michael D. Taylor,Michelle Monje,Yoon Jae Cho,Ravi Majeti,Jens Peter Volkmer,Paul G. Fisher,Gerald A. Grant,Gary K. Steinberg,Hannes Vogel,Michael S. B. Edwards,Irving L. Weissman,Samuel H. Cheshier +36 more
TL;DR: The effect of a humanized anti-CD47 antibody, Hu5F9-G4, is demonstrated to be a potentially safe and effective therapeutic agent for managing multiple pediatric central nervous system malignancies.
Journal ArticleDOI
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
Badreddin Edris,Kipp Weiskopf,Anne Kathrin Volkmer,Jens-Peter Volkmer,Stephen B. Willingham,Humberto Contreras-Trujillo,Jie Liu,Ravindra Majeti,Robert B. West,Jonathan A. Fletcher,Andrew H. Beck,Irving L. Weissman,Matt van de Rijn +12 more
TL;DR: Interference with CD47 increases phagocytosis of two human LMS cell lines, LMS04 and LMS05, in vitro, which suggests that treatment with anti-CD47 antibodies not only reduces primary tumor size but can also be used to inhibit the development of, or to eliminate, metastatic disease.